Kidney derived stem cells and methods for their isolation, differentiation and use

• US 20060177925A1
• Filed: 02/28/2006
• Published: 08/10/2006
• Est. Priority Date: 08/29/2003
• Status: Abandoned Application

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Gupta, Sandeep, Rosenberg, Mark E.
• Application Number:
  US11/364,511
• Publication Number:
  US 20060177925A1
• Time in Patent Office: Days
• US Class Current: 435/353
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/42 Organic phosphate, e.g. beta glycerophosphate
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0686 Kidney cells

Abstract

The invention relates generally to methods for isolation and culture of kidney stem cells, cells isolated by the methods, and therapeutic uses for those cells.

Claims

1. An isolated or purified mammalian multipotent renal progenitor cell (MRPC) that is antigen positive for vimentin and Oct-4, and is antigen negative for zona occludens, cytokeratin, and major histocompatibility Class I and II molecules.

2. The isolated cell of claim 1, wherein the cell is antigen positive for CD90 and CD44.

3. The isolated cell of claims 1 or 2, wherein the cell antigen negative for SSEA-1, NCAM, CD 11b, CD45, CD31, and CD106.

4. The isolated or purified cell of claim 1, wherein the cell is a non-embryonic, non-gern cell line cell.

5. The isolated cell of claim 1, wherein the cell has the capacity to be induced to differentiate to form at least one differentiated cell type of mesodermal, ectodermal and endodermal origin.

6. The isolated cell of claim 1, wherein the cell has the capacity to be induced to differentiate to form cells of at least kidney, endothelium, neuron, or liver cell type.

7. The isolated cell of claim 5, wherein differentiation is induced in vivo or ex vivo.

8. The isolated cell of claim 1, wherein the cell is a human cell.

9. The isolated cell of claim 1, wherein the cell is a mouse cell.

10. The isolated cell of claim 1, wherein the cell is a rat cell.

11. The isolated cell of claim 1, wherein the cell is from a fetus, newborn, child, or adult.

12. The isolated cell of claim 1, wherein the cell is from a newborn, child, or adult.

13. The isolated cell of claim 1, wherein the cell expresses high levels of telomerase and maintains long telomeres after extended in vitro culture.

14. The isolated cell claim 13, wherein the cell maintains telomeres of about 23 Kb in length after extended in vitro culture.

15. A composition comprising a population of the MRPCs of claim 1 and a culture medium, wherein the MRPCs expand in said culture medium.

16. The composition of claim 15, wherein the medium comprises platelet derived growth factor (PDGF-BB), epidermal growth factor (EGF), and leukemia inhibitory factor (LIF).

17. The composition of claim 15, wherein the MRPCs can differentiate to form at least one differentiated cell type of mesodermal, ectodermal and endodermal origin.

18. A differentiated progeny cell obtained from the isolated MRPC of claim 1, wherein the progeny cell is a kidney, endothelium, neuron, or liver cell.

19. The differentiated progeny cell of claim 18, wherein the kidney cell is a tubule cell.

20. An isolated or purified transgenic mammalian multipotent renal progenitor cell (MRPC) comprising the isolated MRPC of claim 1, wherein its genome has been altered by insertion of preselected isolated DNA, by substitution of a segment of the cellular genome with preselected isolated DNA, or by deletion of or inactivation of at least a portion of the cellular genome.

21. The isolated transgenic cell of claim 20, wherein the genome is altered by viral transduction.

22. The isolated transgenic cell of claim 20, wherein the genome is altered by insertion of DNA by viral vector integration.

23. The isolated transgenic cell of claim 21, wherein the genome is altered by using a DNA virus, RNA virus or retroviral vector.

24. The isolated transgenic cell of claim 20, wherein a portion of the cellular genome is inactivated using an antisense nucleic acid molecule whose sequence is complementary to the sequence of the portion of the cellular genome to be inactivated.

25. The isolated transgenic cell of claim 20, wherein a portion of the cellular genome is inactivated using a ribozyme sequence directed to the sequence of the portion of the cellular genome to be inactivated.

26. The isolated transgenic cell of claim 20, wherein a portion of the cellular genome is inactivated using a siRNA sequence directed to the sequence of the portion of the cellular genome to be inactivated.

27. The isolated transgenic cell of claim 20, wherein the altered genome contains a genetic sequence which codes for a selectable or screenable marker that is expressed so that the progenitor cell with the altered genome, or its progeny, can be differentiated from progenitor cells having an unaltered genome.

28. The isolated transgenic cell of claim 27, wherein the marker is a green, red, or yellow fluorescent protein, β

-galactosidase, neomycin phosphotransferase (NPT), dihydrofolate reductase (DHFR^m), or hygromycin phophotransferase (hpt).

29. The isolated transgenic cell of claim 20, wherein the cell expresses a gene that can be regulated by an inducible promoter or other control mechanism to regulate the expression of a protein, enzyme or other cell product.

46. A method of treatment comprising administering to a subject in need thereof a therapeutically effective amount of cells of claim 1 or their progeny.

47. The method of claim 46, wherein the progeny can further differentiate.

48. The method of claim 46, wherein the progeny are terminally differentiated.

49. The method of claim 46, wherein the MRPCs or their progeny home to one or more organs in the subject and are engrafted therein or thereon such that the function of the organ, defective due to injury or disease, is augmented, reconstituted or provided for the first time.

50. A method of using the isolated cell of claim 1, comprising in utero transplantation of a population of the cells to form chimerism of cells or tissues, thereby producing human cells in prenatal or post-natal humans or animals following transplantation, wherein the cells produce therapeutic products in the human or animal so that genetic defects are treated.

51. A method of using the isolated cells of claim 1, for gene therapy in a subject in need of therapeutic treatment, comprising:

(a) genetically altering the cells by introducing into the cell an isolated pre-selected DNA encoding a desired gene product,

(b) expanding the cells in culture; and

(c) adminstering the cells to the subject to produce the desired gene product.

52. A method of repairing damaged tissue in a subject in need of such repair, the method comprising:

(a) expanding the isolated MRPCs of claim 1 in culture; and

(b) administering an effective amount of the expanded cells to the subject with the damaged tissue.

53. The method of claim 51, wherein endogenous MRPCs are stimulated to proliferate and differentiate into different cell lineages of the kidney following administration of exogenous molecules.

55. A method for inducing an immune response to an infectious agent in a subject comprising

(a) providing a genetically altered, expanded clonal population of multipotent renal progenitor cells of claim 1 in culture to express one or more pre-selected antigenic molecules that elicit a protective immune response against an infectious agent, and

(b) administering to the subject an amount of the genetically altered cells effective to induce the immune response.

57. A method for treating cancer in a subject comprising

(a) providing genetically altered multipotent renal progenitor cells of claim 1 that express a tumoricidal protein, an anti-angiogenic protein, or a protein that is expressed on the surface of a tumor cell in conjunction with a protein associated with stimulation of an immune response to antigen, and

(b) adminstering an effective anti-cancer amount of the genetically altered multipotent adult stem cells to subject.

59. A bioartificial kidney device comprising the isolated MRPCs of claim 1 or a cell differentiated therefrom and a device.

60. A method for removing toxins from the blood of a subject comprising contacting blood ex vivo with the isolated MRPCs of claim 1 or cells differentiated therefrom, wherein said cells line a hollow, fiber based device.

70. A method of identifying pharmaceutical agents that facilitate renal cell lineage progression comprising the steps of:

(a) transfecting MRPCs of claim 1 with a promoter region of a gene that is activated during the process of nephron formation, wherein the promoter region is operably linked to a reporter gene;

(b) contacting the transfected cells of (a) with a pharmaceutical agent; and

(c) detecting an expressed protein coded by the marker gene, wherein detection of the protein identifies a pharmaceutical agent as one that facilitates renal cell lineage progression.

71. The method of claim 70, wherein the reporter gene codes for a green, red, or yellow fluorescent protein, β

-galactosidase, neomycin phosphotransferase (NPT), dihydrofolate reductase (DHFR^m), or hygromycin phophotransferase (hpt).

30. A method for isolating a multipotent renal progenitor cell (MRPC), comprising:

(a) culturing renal cells in an aqueous medium consisting essentially of DMEM-LG, MCDB-201, insulin-transferrin-selenium (ITS), dexamethasone, ascorbic acid 2-phosphate, penicillin, streptomycin and fetal calf serim (FCS) and platelet derived growth factor (PDGF-BB), epidermal growth factor (EGF), and leukemia inhibitory factor (LIF) for about four weeks.

31. The method of claim 30, wherein the cells are cultured for about 4 to 6 weeks.

32. The method of claim 30, wherein the cells are cultured on fibronectin.

33. The method of claim 30, wherein the cells are maintained at a concentration of between about 2 and 5×

10² cells/cm².

34. A renal cell isolated by the method of claim 30.

35. A cultured clonal population of mammalian multipotent renal progenitor cells isolated according to the method of claim 30.

36. A method for differentiating MRPCs ex vivo comprising culturing the cells obtained from the method of claim 30 in the presence of preselected differentiation factors.

37. The method of claim 36, wherein the differentiation factors are selected from the group consisting of FGF2, TGF-β

, LIF, VEGF, bFGF, FGF-4, hepatocyte growth factor, or a combination thereof.

38. A differentiated cell obtained by the method of claim 36

39. The differentiated cell of claim 38, wherein the cell is an ectoderm, mesoderm or endoderm cell.

40. The differentiated cell of claim 38, wherein the cell is of the kidney, endothelium, neuron, or liver cell type.

41. The differentiated cell of claim 40, wherein the kidney cell is a tubule cell.

42. A method for differentiating MRPCs in vivo comprising isolating MRPCs according to the method of claim 30, expanding the cells in vitro and administering the expanded cells to a subject, wherein said cells are engrafted and differentiated in vivo into tissue specific cells, so that the function of a cell or organ that is defective due to injury or disease is augmented, reconstituted or provided for the first time.

43. The method of claim 42, wherein the tissue specific cells are of the kidney, endothelium, neuron, or liver cell type.

44. The method of claim 43, wherein the tissue specific cells are of the kidney cell type.

45. A differentiated cell obtained by the method of claim 42.

61. The method of claim 42, wherein the injury is a kidney injury.

62. The method of claim 42, wherein the cells are administered in conjunction with a pharmaceutically acceptable matrix.

63. The method of claim 62, wherein the matrix is biodegradable.

64. The method of claim 62, wherein the matrix implant provides additional genetic material, cytokines, growth factors, or other factors to promote growth and differentiation of the cells.

65. The method of claim 42, wherein the cells are encapsulated prior to administration.

66. The method of claim 65, wherein the encapsulated cells are contained within a polymer capsule.

67. The method of claim 42, wherein the administration is via localized injection, systemic injection, oral administration, or intrauterine injection into an embryo.

68. The method of claim 42, wherein the subject is a mammal.

69. The method of claim 68, wherein the mammal is human.

54. A method of repairing damaged tissue in a subject in need of such repair comprising administering exogenous molecules to a subject so that endogenous MRPCs are stimulated to proliferate and differentiate into different cell lineages of the kidney.

56. A method of using MRPCs to identify genetic polymorphisms associated with physiologic abnormalities, comprising

(a) isolating the MRPCs from a statistically significant population of individuals from whom phenotypic data can be obtained,

(b) expanding the MRPCs from the statistically significant population of individuals in culture to establish MRPC cultures,

(c) identifying at least one genetic polymorphism in the cultured MRPCs,

(d) inducing the cultured MRPCs to differentiate, and

(e) characterizing aberrant metabolic processes associated with the at least one genetic polymorphism by comparing the differentiation pattern exhibited by an MRPC having a normal genotype with the differentiation pattern exhibited by an MRPC having an identified genetic polymorphism.

58. A method of using MRPCs to characterize cellular responses to biologic or pharmacologic agents comprising

(a) culture expanding the MRPCs isolated from a statistically significant population of individuals so as to establish a plurality of MRPC cultures,

(b) contacting the MRPC cultures with one or more biologic or pharmacologic agents,

(c) identifying one or more cellular responses to the one or more biologic or pharmacologic agents, and

(d) comparing the one or more cellular responses of the MRPC cultures from individuals in the statistically significant population.